We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Study to Examine Whether Rapid COVID-19 Antigen Tests Can Identify Infectious and Asymptomatic Individuals

By LabMedica International staff writers
Posted on 28 Oct 2020
Researchers are using rapid COVID-19 antigen tests in a study to examine their use among first responders and school-aged children, as well as understand whether these tests can identify infectious and asymptomatic individuals.

The study by researchers at the University of Southern California (Los Angeles, CA, USA) will examine the use of coronavirus rapid antigen tests among first responders and school-aged children. More...
The pilot study aims to determine the best methods for using the inexpensive tests with the hope of supporting reopening efforts. Rapid tests have the potential to quickly alert people who are contagious and need to isolate, thereby stopping the chain of transmission. Los Angeles is one of the first metropolitan areas in the country to launch a large-scale pilot study of rapid tests in both symptomatic and asymptomatic participants.

The first phase of the new project kicked off recently with firefighters at the Los Angeles Fire Department receiving three COVID-19 tests at city testing sites: a self-administered rapid antigen test, a lab-based PCR test and an antibody test to identify prior infection. The project, which aims to enroll up to 1,000 first responders, will provide insight into how each test performs and how to best administer these tests to essential frontline workers. The second phase of the project seeks to assess the feasibility, acceptability and accuracy of repeat rapid antigen testing for screening in school-aged children.

Researchers are looking at the pilot studies, focus groups and surveys as avenues to tackle a number of challenges, such as establishing the best way to deploy rapid testing, determining how often a person should repeat testing and identifying the best way to conduct large-scale testing and develop an effective implementation strategy.

“Rapid antigen tests have a lot of promise in our path to reopen schools and businesses because they are cheaper and provide quicker results than PCR tests. But there is a lot we don’t know,” said Neeraj Sood, director of the COVID Initiative at the USC Schaeffer Center for Health Policy & Economics and USC lead on the collaboration. “We want to understand whether rapid antigen tests identify infectious and asymptomatic individuals, whether they can be self-administered and how they can be used for screening at schools and workplaces. We are especially excited to be piloting a new rapid antigen test and mobile app that uses computer vision technology to automatically interpret results.”

Related Links:
University of Southern California


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.